Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Lung02
NL-OMON56070Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56070.